Author: Louis Navellier, Investor Place

It gets an “A” rating with triple-digit gains so far in 2020 and a suite of products that are rapidly gaining customers.

It’s more than a great dividend payer– it’s a bona fide biopharmaceutical leader.

I’ve run my Portfolio Grader screens, and these are all A-rated winners that are perfect fits in anyone’s portfolio.

It’s downright cheap and a solid pick for any growth investor.